Search - tctmd.com

Displaying 301 - 320 of 1387

Sort: Relevancy | Date

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Conference News TCT 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

Todd Neale

October 31, 2023

Presentation TCT 2023

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

Presenter: Michael Bloch

October 25, 2023

Presentation TCT 2023

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

Presenter: Felix Mahfoud

October 25, 2023

Presentation TCT 2023

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

Presenter: Ron miller

October 25, 2023

Presentation TCT 2023

TCT 3: Renal Artery Denervation Combined with Pulmonary Vein Isolation in Patients with Heart Failure and Atrial Fibrillation - Pilot Study

Presenter: Tomasz Skowerski

October 25, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

Presentation TCT 2023

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

Presenter: Hamza Naveed

October 25, 2023

Presentation TCT 2023

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Presenter: Michel Azizi

October 25, 2023

Presentation TCT 2023

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

Presenter: Victor Zeijen

October 25, 2023

Presentation TCT 2023

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

Presenter: Karl Fengler

October 25, 2023

Presentation TCT 2023

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Presenter: Anna Subbotina

October 25, 2023

Presentation TCT 2023

Clinician Perspectives

Presenter: Naomi Fisher

October 24, 2023

Presentation TCT 2023

Industry Perspectives

Presenter: Sandeep Brar

October 24, 2023

Presentation TCT 2023

Trialist Perspectives

Presenter: Felix Mahfoud

October 24, 2023

News Daily News

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

Yael L. Maxwell

October 12, 2023

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

L.A. McKeown

October 10, 2023

Advertisement

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Approves Paradise Renal Denervation System: What Comes Next?

What’s Going to Be Hot at AHA 2023

November 2023 News Roundup

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

TCT 3: Renal Artery Denervation Combined with Pulmonary Vein Isolation in Patients with Heart Failure and Atrial Fibrillation - Pilot Study

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Clinician Perspectives

Industry Perspectives

Trialist Perspectives

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content